Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCL

  • End date
    May 5, 2025
  • participants needed
  • sponsor
    Sun Yat-sen University
Updated on 26 May 2022
hodgkin's disease
burkitt's lymphoma
diffuse large b-cell lymphoma
b-cell lymphoma
large b-cell lymphoma


The trial SCCCG-BL/DLBCL-2017 is a collaborative prospective, multicenters, non-randomized, observational, cohort clinical study with participating centers of the South China Children's Cancer Group-Non-Hodgkin lymphoma group(SCCCG-NHL). The aim of the study is to evaluate efficacy and safety of stratified treatment based on risk factors of childhood and adolescents Burkitt lymphoma(BL)/diffuse large B-cell lymphoma(DLBCL) patients in china.


Research purposes:

  1. To investigate the efficacy and safety of SCCCG-BL/DLBCL-2017 in children with BL and DLBCL.
  2. To investigate the effect of rituximab combined with chemotherapy on the survival rate of children with high-risk BL/DLBCL.
  3. To investigate the effect of rituximab on immune function in children with high-risk BL/DLBCL.
  4. To explore the correlation between MRD detection and the efficacy and survival of children with BL/DLBCL.
  5. To explore the role of PET/CT in evaluating residual lesions in children after BL/DLBCL treatment.

Condition Rituximab, Lymphoma, Non-Hodgkin, Pediatric Cancer
Clinical Study IdentifierNCT03958916
SponsorSun Yat-sen University
Last Modified on26 May 2022


Yes No Not Sure

Inclusion Criteria

Age < 18 years old
Pathologically confirmed Burkitt lymphoma or diffuse large B-cell lymphoma
Newly diagnosed patients
Informed consent of guardian of children patients

Exclusion Criteria

Pathological components with follicular lymphoma
Immunodeficiency Second neoplasm
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note